BioNxt Begins Lab-Scale Development of Semaglutide Oral Film

BioNxt Solutions Inc. has received the Semaglutide active pharmaceutical ingredient (API) to start laboratory-scale formulation for its oral dissolvable film (ODF) system. This marks a significant step in the development of the company's drug delivery technology. The API's characteristics, such as solubility and stability, are crucial for optimal formulation.

BioNxt's initial R&D will focus on drug incorporation within the film and testing stability under formulation conditions. Conducted at Gen-Plus GmbH, their European hub, this project utilizes advanced facilities and expertise in polymer science. The goal is to generate first-generation film prototypes and support a provisional patent filing by Q3 2025.

Semaglutide, well-known in diabetes and obesity treatment, had sales exceeding USD 29.3 billion in 2024. BioNxt aims to enhance patient compliance with a non-invasive delivery format. This is the first of several GLP-1-based therapies using their ODF platform.